COOPERATIVE MANAGEMENT OF NEUROSURGEON AND OTOLARYNGOLOGIST IN TREATMENT OF CHILDREN WITH

Insights

This study reviewed 47 pediatric cases of brain infections originating from the ear or sinuses. Effective treatment for these severe suppurative brain diseases requires a collaborative interdisciplinary medical team approach.

Area of Science:

  • Pediatric Neurology
  • Neurosurgery
  • Infectious Diseases

Background:

  • Suppurative meningoencephalitis, brain abscesses, and empyemas in children can arise from otogenic (ear) or rhinosinusogenic (sinus) infections.
  • These conditions represent serious neurological threats in pediatric populations.

Purpose of the Study:

  • To analyze treatment strategies, diagnostic measures, and outcomes for children with oto- and rhinosinusogenic suppurative brain diseases.
  • To emphasize the necessity of a multidisciplinary approach in managing these complex pediatric neurological infections.

Main Methods:

  • Retrospective analysis of 47 pediatric cases (3 months to 17 years old) diagnosed with oto- and rhinosinusogenic suppurative brain diseases.
  • Review of implemented treatment protocols, diagnostic workups, and patient outcomes.

Main Results:

  • The study identified key diagnostic and therapeutic interventions for these pediatric brain infections.
  • Successful management was associated with the coordinated efforts of various medical specialists.

Conclusions:

  • Care for children with oto- and rhinosinusogenic suppurative brain diseases necessitates an interdisciplinary approach.
  • Effective collaboration among neurosurgeons, otolaryngologists, pediatricians, resuscitation specialists, infectionists, and clinical pharmacologists is crucial for optimal patient outcomes.

Related Concept Videos

Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.7K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

3.1K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

2.7K
Cooperative Binding of Transcription Regulators02:13

Cooperative Binding of Transcription Regulators

Transcriptional regulators bind to specific cis-regulatory sequences in the DNA to regulate gene transcription. These cis-regulatory sequences are very short, usually less than ten nucleotide pairs in length. The short length means that there is a high probability of the exact same sequence randomly occurring throughout the genome.  Since regulators can also bind to groups of similar sequences, this further increases the chances of random binding. Transcriptional regulators form...
7.4K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
952